EFTA00506157Set 9
46p3,296w
therapy
• Monoclonals are big ($26B in 2010), polyclonals are
better
• Polyclonal production available in Q4, 2012
• "Killer app" in hospital acquired infections
$25M needed to reach $200M enterprise value ... production
of humanized polyclonal antibodies that are specific to a disease (in Q4, 2012),
which will occur well in advance of an FDA approval of an actual polyclonal
product
https://www.justice.gov/epstein/files/DataSet%209/EFTA00506157.pdf
EFTA02518324Set 11
2014-08-283p176w
Total
&nbs=; 3,455,586
Ou=standing Heritatge
Fund IV Q4 2012 179,762
Fund V Q2 2013 2,614,177
Fund V Q3 2013 521,680
Fund IV Q4
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02518324.pdf